Table 1 Demographic characteristics, diagnostic testing SARS-CoV-2 infection of febrile neonates and infants 90 days or younger, before and during the COVID-19 pandemic
Total (n = 442) | Prepandemic cohort | Pandemic cohort | p-value | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar 2017- Feb 2018(n = 82) | Mar 2018- Feb 2019(n = 65) | Mar 2019- Feb 2020(n = 102) | Mar 2020-Feb 2021(n = 46) | Mar 2021-Feb 2022(n = 79) | Mar 2022- Dec 2022*(n = 68) | |||||||||||
No | (%) | No | (%) | No | (%) | No | (%) | No | (%) | No | (%) | No | (%) | |||
Gender | Female | 187 | (42.3) | 35 | (42.7) | 29 | (44.6) | 40 | (39.2) | 18 | (39.1) | 34 | (43.0) | 31 | (45.6) | 0.958 |
Male | 255 | (57.7) | 47 | (57.3) | 36 | (55.4) | 62 | (60.8) | 28 | (60.9) | 45 | (57.0) | 37 | (54.1) | ||
Age group (days) | 0–21 | 121 | (27.4) | 27 | (32.9) | 16 | (24.6) | 26 | (25.5) | 14 | (30.4) | 18 | (22.8) | 20 | (29.4) | 0.613 |
22–28 | 56 | (12.7) | 11 | (13.4) | 12 | (18.5) | 15 | (14.7) | 4 | (8.7) | 6 | (7.6) | 8 | (11.8) | ||
29–60 | 181 | (41.0) | 26 | (31.7) | 26 | (40.0) | 47 | (46.1) | 17 | (37.0) | 38 | (48.1) | 27 | (39.7) | ||
61–90 | 84 | (19.0) | 18 | (22.0) | 11 | (16.9) | 14 | (13.7) | 11 | (23.9) | 17 | (21.5) | 13 | (19.1) | ||
Median (IQR) | 35 | (20–55) | 30 | (18–57) | 34 | (22–54) | 33 | (21–50) | 36.5 | (17–58) | 43 | (24–60) | 34 | (17–50) | 0.333 | |
Comorbidities | None | 370 | (83.7) | 71 | (86.6) | 57 | (87.69) | 89 | (87.3) | 37 | (80.4) | 61 | (77.2) | 55 | (80.9) | 0.670 |
One | 62 | (14.0) | 10 | (12.2) | 7 | (10.77) | 10 | (9.8) | 7 | (15.2) | 16 | (20.3) | 12 | (17.7) | ||
Two or more | 10 | (2.3) | 1 | (1.2) | 1 | (1.54) | 3 | (2.9) | 2 | (4.3) | 2 | (2.5) | 1 | (1.5) | ||
Premature birth | 24 | (5.5) | 4 | (5.0) | 4 | (6.2) | 5 | (4.9) | 3 | (6.5) | 4 | (5.1) | 4 | (5.9) | 0.998 | |
SARS-CoV-2 | Positive result | 71 | (16.1) | n.a | - | n.a | - | n.a | - | 11 | (23.9) | 25 | (31.6) | 35 | (51.5) | |